RxDoctor Payments Data

Munir Salimi, MD

Internal Medicine · Olean, NYNPI 1134210560

Payments from drug & device makers

$1,490in general payments, 2019–2025

Across 80 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$382
  • GSK$337
  • AstraZeneca$316
  • Inari Medical, Inc.$132
  • Electromed, Inc.$63
  • Pulmonx Corporation$43
  • plus $217 from 9 others

What the payments were for

  • Food & beverage$1,47599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,490 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$45,257
Medicare patients
125
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$85,617
Stiolto RespimatTiotropium Br/Olodaterol Hcl54$37,475
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$35,727
Spiriva RespimatTiotropium Bromide33$35,239
EliquisApixaban31$34,785
JanuviaSitagliptin Phosphate21$29,368
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$29,129
XareltoRivaroxaban21$17,537
JardianceEmpagliflozin18$16,705
Combivent RespimatIpratropium/Albuterol Sulfate15$12,560
Incruse ElliptaUmeclidinium Bromide26$12,345
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$7,680
Albuterol Sulfate HfaAlbuterol Sulfate145$7,521
Atrovent HfaIpratropium Bromide12$6,850
SymbicortBudesonide/Formoterol Fumarate11$6,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$337$133,688170 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Jardiance, Combivent Respimat$382$101,979120 claims
AstraZenecaBreztri Aerosphere, Symbicort$316$35,48641 claims
PfizerEliquis$11$34,78531 claims
Johnson & JohnsonXarelto$30$17,53721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Olean

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →